{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:10:50Z","timestamp":1792663850720,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00702-017-1825-5","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T01:13:16Z","timestamp":1513213996000},"page":"1137-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-9793","authenticated-orcid":false,"given":"Elisabetta","family":"Tronci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Francardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1172\/JCI90132","volume":"127","author":"C Alcacer","year":"2017","unstructured":"Alcacer C, Andreoli L, Sebastianutto I et al (2017) Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson\u2019s disease therapy. J Clin Investig 127:720\u2013734","journal-title":"J Clin Investig"},{"key":"1825_CR2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1460-9568.1995.tb01085.x","volume":"7","author":"M Amalric","year":"1995","unstructured":"Amalric M, Moukhles H, Nieoullon A, Daszuta A (1995) Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 7:972\u2013980","journal-title":"Eur J Neurosci"},{"key":"1825_CR3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","volume":"6","author":"M Andersson","year":"1999","unstructured":"Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 6:461\u2013474","journal-title":"Neurobiol Dis"},{"key":"1825_CR4","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1007\/s00415-010-5714-1","volume":"257","author":"A Antonini","year":"2010","unstructured":"Antonini A, Ursino G, Calandrella D et al (2010) Continuous dopaminergic delivery in Parkinson\u2019s disease. J Neurol 257:S305\u2013S308","journal-title":"J Neurol"},{"key":"1825_CR5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B et al (2015) Pathophysiology of l-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol 132:96\u2013168","journal-title":"Prog Neurobiol"},{"key":"1825_CR6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biopsych.2009.04.005","volume":"66","author":"O Berton","year":"2009","unstructured":"Berton O, Guigoni C, Li Q et al (2009) Striatal overexpression of DeltaJunD resets l-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 66:554\u2013561","journal-title":"Biol Psychiatry"},{"key":"1825_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nbd.2016.06.005","volume":"94","author":"F Bez","year":"2016","unstructured":"Bez F, Francardo V, Cenci MA (2016) Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. Neurobiol Dis 94:213\u2013225","journal-title":"Neurobiol Dis"},{"key":"1825_CR8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E, Tronci E, Pioli EY et al (2013) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28:1088\u20131096","journal-title":"Mov Disord"},{"key":"1825_CR9","doi-asserted-by":"crossref","first-page":"845618","DOI":"10.1155\/2012\/845618","volume":"2012","author":"J Blesa","year":"2012","unstructured":"Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson\u2019s disease. J Biomed Biotechnol 2012:845618","journal-title":"J Biomed Biotechnol"},{"key":"1825_CR10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","volume":"18","author":"F Bracco","year":"2004","unstructured":"Bracco F, Battaglia A, Chouza C et al (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18:733\u2013746","journal-title":"CNS Drugs"},{"key":"1825_CR11","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1523\/JNEUROSCI.0252-10.2010","volume":"30","author":"X Cao","year":"2010","unstructured":"Cao X, Yasuda T, Uthayathas S et al (2010) Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 30:7335\u20137343","journal-title":"J Neurosci"},{"key":"1825_CR12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200","journal-title":"Nature"},{"key":"1825_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fneur.2014.00078","volume":"5","author":"M Carta","year":"2014","unstructured":"Carta M, Tronci E (2014) Serotonin system implication in l-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 5:78","journal-title":"Front Neurol"},{"key":"1825_CR14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D et al (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"issue":"Suppl 2","key":"1825_CR15","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","volume":"14","author":"M Carta","year":"2008","unstructured":"Carta M, Carlsson T, Mu\u00f1oz A et al (2008) Involvement of the serotonin system in l-dopa-induced dyskinesias. Parkinsonism Relat Disord 14(Suppl 2):S154\u2013S158","journal-title":"Parkinsonism Relat Disord"},{"key":"1825_CR16","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","volume":"25","author":"M Carta","year":"2010","unstructured":"Carta M, Carlsson T, Mu\u00f1oz A et al (2010) Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 25:S174\u2013S179","journal-title":"Mov Disord"},{"key":"1825_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","volume":"183","author":"MA Cenci","year":"2010","unstructured":"Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog Brain Res 183:209\u2013233","journal-title":"Prog Brain Res"},{"key":"1825_CR18","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","volume":"10","author":"MA Cenci","year":"1998","unstructured":"Cenci MA, Lee CS, Bj\u00f6rklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694\u20132706","journal-title":"Eur J Neurosci"},{"issue":"Suppl 3","key":"1825_CR19","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(09)70782-5","volume":"15","author":"MA Cenci","year":"2009","unstructured":"Cenci MA, Ohlin KE, Rylander D (2009) Plastic effects of l-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat Disord 15(Suppl 3):S59\u2013S63","journal-title":"Parkinsonism Relat Disord"},{"key":"1825_CR20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","volume":"15","author":"F Cicchetti","year":"2002","unstructured":"Cicchetti F, Brownell AL, Williams K et al (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991\u2013998","journal-title":"Eur J Neurosci"},{"key":"1825_CR21","first-page":"77","volume":"5","author":"G Cohen","year":"1984","unstructured":"Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5:77\u201382","journal-title":"Neurotoxicology"},{"key":"1825_CR22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0006-8993(90)90088-S","volume":"519","author":"I Date","year":"1990","unstructured":"Date I, Felten DL, Felten SY (1990) Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res 519:266\u2013276","journal-title":"Brain Res"},{"key":"1825_CR23","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","volume":"127","author":"R Fuente-Fern\u00e1ndez de la","year":"2004","unstructured":"de la Fuente-Fern\u00e1ndez R, Sossi V, Huang Z et al (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain 127:2747\u20132754","journal-title":"Brain"},{"key":"1825_CR24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00213-007-0862-4","volume":"194","author":"E Leonibus De","year":"2007","unstructured":"De Leonibus E, Pascucci T, Lopez S et al (2007) Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology 194:517\u2013525","journal-title":"Psychopharmacology"},{"key":"1825_CR25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","volume":"235","author":"M Decressac","year":"2012","unstructured":"Decressac M, Mattsson B, Bj\u00f6rklund A (2012) Comparison of the behavioural and histological characteristics of the 6-OHDA and \u03b1-synuclein rat models of Parkinson\u2019s disease. Exp Neurol 235:306\u2013315","journal-title":"Exp Neurol"},{"key":"1825_CR26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76\u201389","journal-title":"Behav Brain Res"},{"key":"1825_CR27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","volume":"152","author":"M Delfino","year":"2004","unstructured":"Delfino M, Stefano A, Ferrario J et al (2004) Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res 152:297\u2013306","journal-title":"Behav Brain Res"},{"key":"1825_CR28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2007.03.013","volume":"27","author":"Y Ding","year":"2007","unstructured":"Ding Y, Restrepo J, Won L et al (2007) Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson\u2019s disease. Neurobiol Dis 27:11\u201323","journal-title":"Neurobiol Dis"},{"key":"1825_CR29","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357\u20131391","journal-title":"Br J Pharmacol"},{"key":"1825_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991:1\u201314","journal-title":"Ann N Y Acad Sci"},{"key":"1825_CR30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mds.26102","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30:4\u201318","journal-title":"Mov Disord"},{"key":"1825_CR31","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1073\/pnas.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano S, Bezard E, D\u2019Antoni A et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa-induced dyskinesia. Proc Natl Acad Sci USA 107:21824\u201321829","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"1825_CR32","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1353-8020(13)70008-7","volume":"20","author":"V Francardo","year":"2014","unstructured":"Francardo V, Cenci MA (2014) Investigating the molecular mechanisms of l-DOPA-induced dyskinesia in the mouse. Parkinsonism Relat Disord 20(Suppl 1):S20\u2013S22","journal-title":"Parkinsonism Relat Disord"},{"key":"1825_CR33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2011.01.024","volume":"42","author":"V Francardo","year":"2011","unstructured":"Francardo V, Recchia A, Popovic N et al (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to l-DOPA in the 6-hydroxydopamine mouse model of Parkinson\u2019s disease. Neurobiol Dis 42:327\u2013340","journal-title":"Neurobiol Dis"},{"key":"1825_CR34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2015.11.022","volume":"86","author":"V Ghiglieri","year":"2016","unstructured":"Ghiglieri V, Mineo D, Vannelli A et al (2016) Modulation of serotonergic transmission by eltoprazine in l-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms. Neurobiol Dis 86:140\u2013153","journal-title":"Neurobiol Dis"},{"key":"1825_CR35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","volume":"151","author":"B Henry","year":"1998","unstructured":"Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. Exp Neurol 151:334\u2013342","journal-title":"Exp Neurol"},{"key":"1825_CR36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.26947","volume":"32","author":"LF Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez LF, Castela I, Ruiz-DeDiego I et al (2017) Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. Mov Disord 32:530\u2013537","journal-title":"Mov Disord"},{"key":"1825_CR37","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease. Arch Neurol 61:1044\u20131053","journal-title":"Arch Neurol"},{"key":"1825_CR38","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0896-6273(94)90061-2","volume":"13","author":"BT Hope","year":"1994","unstructured":"Hope BT, Nye HE, Kelz MB et al (1994) Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13:1235\u20131244","journal-title":"Neuron"},{"key":"1825_CR100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2012.03.023","volume":"211","author":"H Iderberg","year":"2012","unstructured":"Iderberg H, Francardo V, Pioli EY (2012) Animal models of l-DOPA-induced dyskinesia: an update on the current options. Neurosci 211:13\u201327","journal-title":"Neuroscience"},{"key":"1825_CR39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","volume":"93","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA et al (2015) Activity of serotonin 5-HT(1A) receptor \u201cbiased agonists\u201d in rat models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia. Neuropharmacology 93:52\u201367","journal-title":"Neuropharmacology"},{"key":"1825_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc 2:141\u2013151","journal-title":"Nat Protoc"},{"key":"1825_CR41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs 21:677\u2013692","journal-title":"CNS Drugs"},{"key":"1825_CR42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"D Kirik","year":"1998","unstructured":"Kirik D, Rosenblad C, Bj\u00f6rklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259\u2013277","journal-title":"Exp Neurol"},{"key":"1825_CR43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","volume":"177","author":"HS Lindgren","year":"2007","unstructured":"Lindgren HS, Rylander D, Ohlin KE et al (2007) The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav Brain Res 177:150\u2013159","journal-title":"Behav Brain Res"},{"key":"1825_CR44","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","volume":"112","author":"HS Lindgren","year":"2010","unstructured":"Lindgren HS, Andersson DR, Lagerkvist S et al (2010) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson\u2019s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112:1465\u20131476","journal-title":"J Neurochem"},{"key":"1825_CR45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","volume":"15","author":"M Lundblad","year":"2002","unstructured":"Lundblad M, Andersson M, Winkler C et al (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease. Eur J Neurosci 15:120\u2013132","journal-title":"Eur J Neurosci"},{"key":"1825_CR46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","volume":"16","author":"M Lundblad","year":"2004","unstructured":"Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110\u2013123","journal-title":"Neurobiol Dis"},{"key":"1825_CR47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M et al (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194:66\u201375","journal-title":"Exp Neurol"},{"key":"1825_CR48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JPD-2012-120103","volume":"2","author":"A Manson","year":"2012","unstructured":"Manson A, Stirpe P, Schrag A (2012) Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2:189\u2013198","journal-title":"J Parkinsons Dis"},{"key":"1825_CR49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2003.12.034","volume":"1004","author":"EA Mazzio","year":"2004","unstructured":"Mazzio EA, Reams RR, Soliman KFA (2004) The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res 1004:29\u201344","journal-title":"Brain Res"},{"key":"1825_CR50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nbd.2011.09.015","volume":"45","author":"F Mela","year":"2012","unstructured":"Mela F, Marti M, Bido S et al (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis 45:573\u2013582","journal-title":"Neurobiol Dis"},{"key":"1825_CR51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1006\/bbrc.1998.8986","volume":"248","author":"Y Mitsumoto","year":"1998","unstructured":"Mitsumoto Y, Watanabe A, Mori A, Koga N (1998) Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL\/6 mice. Biochem Biophys Res Commun 248:660\u2013663","journal-title":"Biochem Biophys Res Commun"},{"key":"1825_CR52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","volume":"286","author":"G Mulas","year":"2016","unstructured":"Mulas G, Espa E, Fenu S et al (2016) Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson\u2019s disease. Exp Neurol 286:83\u201392","journal-title":"Exp Neurol"},{"key":"1825_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","volume":"87","author":"A Nadjar","year":"2009","unstructured":"Nadjar A, Gerfen CR, Bezard E (2009) Priming for l-dopa-induced dyskinesia in Parkinson\u2019s disease: a feature inherent to the treatment or the disease? Prog Neurobiol 87:1\u20139","journal-title":"Prog Neurobiol"},{"key":"1825_CR54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mds.21235","volume":"22","author":"AP Nicholas","year":"2007","unstructured":"Nicholas AP (2007) Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov Disord 22:99\u2013104","journal-title":"Mov Disord"},{"key":"1825_CR55","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Agid Y, Mizuno Y et al (2004) Levodopa in the treatment of Parkinson\u2019s disease: current controversies. Mov Disord 19:997\u20131005","journal-title":"Mov Disord"},{"key":"1825_CR56","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","volume":"15","author":"M Olsson","year":"1995","unstructured":"Olsson M, Nikkhah G, Bentlage C, Bj\u00f6rklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863\u20133875","journal-title":"J Neurosci"},{"key":"1825_CR57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mds.21308","volume":"22","author":"V Paill\u00e9","year":"2007","unstructured":"Paill\u00e9 V, Henry V, Lescaudron L et al (2007) Rat model of Parkinson\u2019s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord 22:533\u2013539","journal-title":"Mov Disord"},{"key":"1825_CR58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","volume":"662","author":"SM Papa","year":"1994","unstructured":"Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69\u201374","journal-title":"Brain Res"},{"key":"1825_CR59","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/j.1460-9568.2011.07704.x","volume":"33","author":"M Papathanou","year":"2011","unstructured":"Papathanou M, Rose S, McCreary A, Jenner P (2011) Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. Eur J Neurosci 33:2247\u20132254","journal-title":"Eur J Neurosci"},{"key":"1825_CR60","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","volume":"36","author":"MA Paquette","year":"2012","unstructured":"Paquette MA, Martinez AA, Macheda T et al (2012) Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson\u2019s disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci 36:3224\u20133234","journal-title":"Eur J Neurosci"},{"key":"1825_CR61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","volume":"59","author":"N Pav\u00f3n","year":"2006","unstructured":"Pav\u00f3n N, Mart\u00edn AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64\u201374","journal-title":"Biol Psychiatry"},{"key":"1825_CR62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.freeradbiomed.2013.05.042","volume":"62","author":"R Perfeito","year":"2013","unstructured":"Perfeito R, Cunha-Oliveira T, Rego AC (2013) Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease\u2014resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 62:186\u2013201","journal-title":"Free Radic Biol Med"},{"key":"1825_CR63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2007.10.001","volume":"29","author":"B Picconi","year":"2008","unstructured":"Picconi B, Paill\u00e9 V, Ghiglieri V et al (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327\u2013335","journal-title":"Neurobiol Dis"},{"key":"1825_CR64","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12640-013-9446-8","volume":"25","author":"A Pinna","year":"2014","unstructured":"Pinna A, Morelli M (2014) A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: the case of adenosine A2A receptor antagonists. Neurotox Res 25:392\u2013401","journal-title":"Neurotox Res"},{"key":"1825_CR65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/mds.26475","volume":"31","author":"A Pinna","year":"2015","unstructured":"Pinna A, Ko WK, Costa G et al (2015) Antidyskinetic effect of A2A and 5HT1A\/1B receptor ligands in two animal models of Parkinson\u2019s disease. Mov Disord 31:501\u2013511","journal-title":"Mov Disord"},{"key":"1825_CR66","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis M, Wu K, Loane C et al (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Investig 124:1340\u20131349","journal-title":"J Clin Investig"},{"key":"1825_CR67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","volume":"67","author":"S Przedborski","year":"1995","unstructured":"Przedborski S, Levivier M, Jiang H et al (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631\u2013647","journal-title":"Neuroscience"},{"key":"1825_CR68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.107.126219","volume":"323","author":"DB Putterman","year":"2007","unstructured":"Putterman DB, Munhall AC, Kozell LB et al (2007) Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. J Pharmacol Exp Ther 323:277\u2013284","journal-title":"J Pharmacol Exp Ther"},{"key":"1825_CR69","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"1825_CR70","doi-asserted-by":"crossref","first-page":"e90759","DOI":"10.1371\/journal.pone.0090759","volume":"9","author":"G Sahin","year":"2014","unstructured":"Sahin G, Thompson LH, Lavisse S et al (2014) Differential dopamine receptor occupancy underlies l-DOPA-induced dyskinesia in a rat model of parkinson\u2019s disease. PLoS One 9:e90759","journal-title":"PLoS One"},{"key":"1825_CR71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0006-8993(94)91533-4","volume":"633","author":"K Sakai","year":"1994","unstructured":"Sakai K, Gash DM (1994) Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. Brain Res 633:144\u2013150","journal-title":"Brain Res"},{"key":"1825_CR72","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","volume":"27","author":"E Santini","year":"2007","unstructured":"Santini E, Valjent E, Usiello A et al (2007) Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J Neurosci 27:6995\u20137005","journal-title":"J Neurosci"},{"key":"1825_CR73","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","volume":"5","author":"H Sawada","year":"2010","unstructured":"Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS One 5:e15298","journal-title":"PLoS One"},{"key":"1825_CR74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","volume":"50","author":"RK Schwarting","year":"1996","unstructured":"Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275\u2013331","journal-title":"Prog Neurobiol"},{"key":"1825_CR75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.nbd.2016.09.001","volume":"96","author":"I Sebastianutto","year":"2016","unstructured":"Sebastianutto I, Maslava N, Hopkins CR, Cenci MA (2016) Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis 96:156\u2013170","journal-title":"Neurobiol Dis"},{"key":"1825_CR76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1001958023096","volume":"30","author":"M Sedelis","year":"2000","unstructured":"Sedelis M, Hofele K, Auburger GW et al (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171\u2013182","journal-title":"Behav Genet"},{"key":"1825_CR77","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","volume":"62","author":"F Stocchi","year":"2005","unstructured":"Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905\u2013910","journal-title":"Arch Neurol"},{"key":"1825_CR78","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T et al (1999) Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10:631\u2013634","journal-title":"NeuroReport"},{"key":"1825_CR79","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pbb.2005.06.013","volume":"81","author":"JL Taylor","year":"2005","unstructured":"Taylor JL, Bishop C, Walker PD (2005) Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81:887\u2013893","journal-title":"Pharmacol Biochem Behav"},{"key":"1825_CR80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neures.2012.03.004","volume":"73","author":"E Tronci","year":"2012","unstructured":"Tronci E, Shin E, Bj\u00f6rklund A, Carta M (2012) Amphetamine-induced rotation and l-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci Res 73:168\u2013172","journal-title":"Neurosci Res"},{"key":"1825_CR81","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2013.08.014","volume":"60","author":"E Tronci","year":"2013","unstructured":"Tronci E, Lisci C, Stancampiano R et al (2013) 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson\u2019s disease model. Neurobiol Dis 60:108\u2013114","journal-title":"Neurobiol Dis"},{"key":"1825_CR82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4471-6503-3_11","volume-title":"Levodopa-Induced Dyskinesia in Parkinson's Disease","author":"E Tronci","year":"2014","unstructured":"Tronci E, Fidalgo C, Carta M (2014) The serotonergic system in l-DOPA-induced dyskinesia. In: Fox S, Brotchie J (eds) Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer, London, pp 199\u2013212"},{"key":"1825_CR83","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbr.2015.06.034","volume":"292","author":"E Tronci","year":"2015","unstructured":"Tronci E, Fidalgo C, Stancampiano R, Carta M (2015) Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats. Behav Brain Res 292:300\u2013304","journal-title":"Behav Brain Res"},{"key":"1825_CR84","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1073\/pnas.1003432107","volume":"107","author":"A Ulusoy","year":"2010","unstructured":"Ulusoy A, Sahin G, Kirik D (2010) Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci 107:13159\u201313164","journal-title":"Proc Natl Acad Sci"},{"key":"1825_CR85","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107\u2013110","journal-title":"Eur J Pharmacol"},{"key":"1825_CR86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69\u201393","journal-title":"Acta Physiol Scand Suppl"},{"key":"1825_CR87","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","volume":"62","author":"JE Westin","year":"2007","unstructured":"Westin JE, Vercammen L, Strome EM et al (2007) Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62:800\u2013810","journal-title":"Biol Psychiatry"},{"key":"1825_CR88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0079-6123(00)27012-X","volume":"127","author":"C Winkler","year":"2000","unstructured":"Winkler C, Kirik D, Bj\u00f6rklund A, Dunnett SB (2000) Transplantation in the rat model of Parkinson\u2019s disease: ectopic versus homotopic graft placement. Prog Brain Res 127:233\u2013265","journal-title":"Prog Brain Res"},{"key":"1825_CR89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","volume":"10","author":"C Winkler","year":"2002","unstructured":"Winkler C, Kirik D, Bj\u00f6rklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165\u2013186","journal-title":"Neurobiol Dis"},{"key":"1825_CR90","doi-asserted-by":"crossref","first-page":"B473","DOI":"10.1093\/gerona\/55.10.B473","volume":"55","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, Andersen A, Smith C et al (2010) Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci 55:B473\u2013B480","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1825-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:29:18Z","timestamp":1693333758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1825-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":92,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1825-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}